ea0029oc10.5 | Pituitary Clinical 2 | ICEECE2012
Popovic V.
, Goth M.
, Vanuga P.
, Payer J.
, Pfeifer M.
, Bidlingmaier M.
, Fima E.
Objective: GH replacement therapy currently requires daily injections, which may cause poor compliance and distress for patients. CTP-modified hGH (MOD-4023) is being developed for once-weekly administration in GH Deficient adults and children. The present study evaluated the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of MOD-4023 in GHD adults.Design and methods: 39 normalized GHDA patients currently treated with daily GH were randomized and...